(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(1.30%) $1.948
(-0.13%) $2 344.10
(0.15%) $27.58
(0.78%) $929.30
(-0.35%) $0.931
(-0.46%) $10.97
(-0.43%) $0.797
(0.25%) $92.11
0.00% € 0.290
Live Chart Being Loaded With Signals
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology...
Stats | |
---|---|
Dzisiejszy wolumen | 112 228 |
Średni wolumen | 0.00 |
Kapitalizacja rynkowa | 27.24M |
EPS | €0 ( 2024-04-28 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.320 |
ATR14 | €0.00700 (2.41%) |
Wolumen Korelacja
Biocartis Group NV Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Biocartis Group NV Korelacja - Waluta/Towar
Biocartis Group NV Finanse
Annual | 2022 |
Przychody: | €57.48M |
Zysk brutto: | €27.68M (48.16 %) |
EPS: | €-1.080 |
FY | 2022 |
Przychody: | €57.48M |
Zysk brutto: | €27.68M (48.16 %) |
EPS: | €-1.080 |
FY | 2021 |
Przychody: | €48.27M |
Zysk brutto: | €14.35M (29.72 %) |
EPS: | €-0.895 |
FY | 2020 |
Przychody: | €43.13M |
Zysk brutto: | €16.84M (39.06 %) |
EPS: | €-1.110 |
Financial Reports:
No articles found.
Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej